Achieve Life Sciences (Achieve Life Sciences) EV-to-Revenue : (As of Apr. 30, 2024)

View and export this data going back to 1995. Start your Free Trial

What is Achieve Life Sciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Achieve Life Sciences's enterprise value is $157.77 Mil. Achieve Life Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Achieve Life Sciences's EV-to-Revenue for today is .

The historical rank and industry rank for Achieve Life Sciences's EV-to-Revenue or its related term are showing as below:

During the past 13 years, the highest EV-to-Revenue of Achieve Life Sciences was 5.66. The lowest was -2.03. And the median was 1.48.

ACHV's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.775
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-30), Achieve Life Sciences's stock price is $4.57. Achieve Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, Achieve Life Sciences's PS Ratio for today is .

Achieve Life Sciences EV-to-Revenue Historical Data

The historical data trend for Achieve Life Sciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences EV-to-Revenue Chart

Achieve Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

Achieve Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Achieve Life Sciences's EV-to-Revenue

For the Biotechnology subindustry, Achieve Life Sciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achieve Life Sciences's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's EV-to-Revenue falls into.

Achieve Life Sciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Achieve Life Sciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	157.766	/	0
	=

Achieve Life Sciences's current Enterprise Value is $157.77 Mil.
Achieve Life Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Achieve Life Sciences (NAS:ACHV) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Achieve Life Sciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	4.57	/	0
	=

Achieve Life Sciences's share price for today is $4.57.
Achieve Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Achieve Life Sciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Achieve Life Sciences (Achieve Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (NAS:ACHV) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

SP4P:Germany

Address

22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021

Website

https://www.achievelifesciences.com

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.

Executives

John Bencich	officer: CFO and PFO	2401 FOURTH AVENUE, SUITE 1050, SEATTLE WA 98121
Stuart Duty	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Sellig	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Braxton King	director	91 JAMES AVENUE, ATHERTON CA 94027
Dialectic Life Sciences Spv Llc	10 percent owner	C/O DIALECTIC LS MANAGER LLC, 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Ls Manager Llc	10 percent owner	119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
John Fichthorn	10 percent owner	C/O DIALECTIC CAPITAL MANAGEMENT, LLC, 17 STATE STREET, SUITE 3930, NEW YORK NY 10004
Dialectic Capital Management, Lp	10 percent owner	119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Partners, Llc	10 percent owner	2ND FLOOR 119 ROWAYTON AVE, NORWALK CT 06853
Vaughn B Himes	director	C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Financial Group Svb	10 percent owner	2270 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii, Llc	10 percent owner	2770 SAND HILL ROAD, MENLO CITY CA 94025
Svb Innovation Credit Fund Viii, L.p.	10 percent owner	C/O SVB INNOVATION CREDIT PARTNERS VIII, 2770 SAND HILL ROAD, MENLO PARK CA 94025
Innovation Credit Fund Viii-a, L.p.	10 percent owner	2770 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii-a, Llc	10 percent owner	2770 SAND HILL ROAD, MENLO CITY CA 94025